- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00726713
Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)
A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham School of Medicine
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Health Sciences Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105
- Omaha VA Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75230
- Dallas Diabetes and Endocrine Center
-
San Antonio, Texas, United States, 78229
- Dgd Research, Inc.
-
Temple, Texas, United States, 76504
- Scott and White Hospital & Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between 25 and 80 years of age (inclusive);
- Documented diabetes mellitus Type 2 (Based upon ADA criteria);
- Peripheral polyneuropathy: Vibration Perception Threshold (VPT) 25-45 Volts at hallux on either leg.
Adequate lower extremity vascular status:
- Palpable pedal pulse in both feet;
- No intermittent claudication;
- No history of lower extremity vascular bypass surgery or angioplasty
- The subject is able to understand the information in the informed consent form and is willing and able to sign the consent.
Exclusion Criteria:
- Amputation of any kind or an ulceration within the last two (2) years including at Screen;
- History or active Charcot neuroarthropathy on either foot;
- Previous surgery to spine or lower extremity with residual symptoms of pain or difficulty with movement;
- Severe rheumatoid arthritis or osteoarthritis that would cause discomfort during causal walking or stair climbing;
- Current treatment with systemic steroids, immunosuppressives, or radiotherapy;
- Peripheral vascular disease defined as any nonpalpable foot pulse, history of claudication, or a history of lower extremity vascular bypass surgery or angioplasty;
- Glycated hemoglobin (HbA1c) >9 at Screen.
- Uncontrolled heart (Hypertension: BP > 160/90), or lung disease (uncontrolled asthma or shortness of breath) in the last 2 months prior to Screen;
- End stage kidney disorder requiring hemodialysis or serum creatinine > 2.5X (normal upper limit);
- The following supplements within 2 months prior to Screen: alpha lipoic acid; B12 injection; >10mg of B6; or, > 800mcg of folate;
- Taking either an opiate at any dose or on the maximum dose of any anticonvulsant;
- Pregnant or nursing;
- Life expectancy < 12 months;
- Initiated therapies for Painful Diabetic Neuropathy (pregabalin, gabapentin, duloxetine etc.) in the last 2 months prior to Screen;
- Initiated new hyperglycemic, insulin, statin or hypertensive therapies within 2 months prior to Screen (dose modifications of current therapies are allowed at the discretion of the investigator);
- Current alcohol or drug abuse (or history of such abuse within the past 3 years); and,
- Not willing or able to follow procedures specified by the protocol and/or the instructions of the study personnel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
Metanx placebo one tablet twice a day
|
Experimental: 1
Metanx
|
Metanx one tablet twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks
Time Frame: VPT was measured a 0 (baseline), and 24 weeks
|
Vibration Perception Threshold (VPT) 25-45 volts at hallux on either leg as measured by VPT meter on the great toe of each foot.
Mean VPT averaged across both toes.
|
VPT was measured a 0 (baseline), and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Neuropathy Total Symptom Score-6 (NTSS-6)
Time Frame: NTSS-6 scores were taken at 0 (Baseline), 16, and 24 weeks
|
This measure was taken to determine if Metanx® (compared to placebo) changes neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6) The Neuropathy Total Symptom Score-6 Scale (NTSS-6) is a validated scale that evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN). This scale was a modified 6 item scale that consists of yes or no questions. Scores range between 0 and 21.96, a higher score indicates greater severity of symptoms. After adjusting for baseline measurements scores are reflected as negative numbers. Negative numbers indicate improvement in symptoms. ie. a change from baseline after 24 weeks of -2 would be a greater improvement than a change in baseline of -1 after 24 weeks. |
NTSS-6 scores were taken at 0 (Baseline), 16, and 24 weeks
|
Change From Baseline in Neuropathy Disability Score (NDS)at Week 16 and 24
Time Frame: NDS scores were taken at 0 (Baseline), 16, and 24 weeks
|
This outcome was taken to determine if Metanx® (compared to placebo) has an effect on clinical examination as determined by the Neuropathy Disability Score (NDS) The Neuropathy Disability Score (NDS) evaluates the severity of individual symptoms of neuropathy. A simple visual numeric distress scale is used that ranges from 0 to 10. The most favorable score is 0, which indicates an absence of symptoms. The most severe symptoms possible would be recorded as a score of 10. |
NDS scores were taken at 0 (Baseline), 16, and 24 weeks
|
Change From Baseline in Plasma Marker Levels of Total Folate and Total Methyl Malonic Acid (MMA) at Week 16 and 24
Time Frame: Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks
|
To determine if Metanx® (compared to placebo) affects a change in subject's total folate and total methyl malonic acid (MMA) at week 16 and 24
|
Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks
|
Change From Baseline in SF-36 MCS and SF-36 PCS at Week 24
Time Frame: SF-36 MCS and SF-36 PCS scores were measured at 0 (Baseline) and 24 weeks
|
To determine if Metanx® (compared to placebo) affects a subject's "quality of life" as determined by the SF-36 questionnaire The Short Form- 36 Mental Component Summary (SF-36 MCS) and SF-36 Physical Component Summary (SF-36 PCS) both measure health related quality of life, the MCS quantifying mental health and the PCS quantifying physical function. They are both scored on 100 point scales with 0 representing the worst possible outcome and 100 representing the most optimal possible scoring |
SF-36 MCS and SF-36 PCS scores were measured at 0 (Baseline) and 24 weeks
|
Change From Baseline in 10-point Visual Analog Scale(VAS) at Week 24
Time Frame: VAS scores were taken at 0 (Baseline) and 24 weeks
|
To determine if Metanx® (compared to placebo) affects a subject's lower extremity pain level using a 10-point Visual Analog Scale at Baseline and 24-week evaluation visits. The Visual Analog Scale (VAS) measures a patients sensation of pain. A 10-cm visual analog scale is used. A measurement on the 10 cm analog scale is used to quantify the level of pain indicated with 0 cm indicating "no pain" and 10 cm indicating the "worst pain imaginable". |
VAS scores were taken at 0 (Baseline) and 24 weeks
|
(Exploratory) Change From Baseline in Levels of IL-6 and TNF-α, at Week 24
Time Frame: Analyte levels were taken at 0 (Baseline) and 24 weeks
|
(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory marker levels, including IL-6 and TNF-α
|
Analyte levels were taken at 0 (Baseline) and 24 weeks
|
(Exploratory) Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Question Inventory at Week 24
Time Frame: HADS Scores scores were taken at 0 (Baseline) and 24 weeks
|
The Hospital Anxiety and Depression Scale (HADS) consists of a 14-item questionnaire that provides a measurement of depression.
Each item is rated on a 4-point scale, giving a maximum scores of 21 for the most severe depression.
Depression was evaluated using the Hospital Anxiety and Depression Scale (HADS) question inventory at Baseline, and 24-week evaluation visits
|
HADS Scores scores were taken at 0 (Baseline) and 24 weeks
|
Change From Baseline in Total Homocysteine at Week 16 and 24
Time Frame: Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks
|
To determine if Metanx® (compared to placebo) affects change in subjects total homocysteine levels
|
Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks
|
(Exploratory) Change From Baseline in Levels of Hs-CRP at Week 24
Time Frame: Analyte levels were taken at 0 (Baseline) and 24 weeks
|
(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including hs-CRP
|
Analyte levels were taken at 0 (Baseline) and 24 weeks
|
(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24
Time Frame: Analyte levels were taken at 0 (Baseline) and 24 weeks
|
(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including Potential Antioxidant (PAO)
|
Analyte levels were taken at 0 (Baseline) and 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vivian Fonseca, MD, Tulane University Health Sciences Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetic Peripheral Neuropathy (DPN)
-
Riphah International UniversityRecruitingDiabetic Peripheral Neuropathy (DPN)Pakistan
-
Pamlab, L.L.C.HealthCore, Inc.CompletedDiabetic Peripheral Neuropathy (DPN)United States
-
Haisco Pharmaceutical Group Co., Ltd.CompletedParesthesia | Diabetic Peripheral Neuropathy (DPN)China
-
Lateral Pharma Pty LtdCompletedNeuropathic Pain | Diabetic Peripheral Neuropathy (DPN) | Post Herpetic Neuralgia (PHN)Australia, United Kingdom
-
University of MichiganEli Lilly and Company; Amylin Pharmaceuticals, LLC.CompletedType 2 Diabetes Mellitus | Diabetic Peripheral NeuropathyUnited States
-
Istanbul UniversityCompletedDiabetic Neuropathies | Diabetic Neuropathy Peripheral | Type2Diabetes | Cardiac Autonomic Neuropathy | Neuropathy Autonomic
-
Wuhan Central HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China; Wuhan...RecruitingDiabetic Peripheral Neuropathy Type 2China
-
Fengmei LianPeking Union Medical College Hospital; Huashan Hospital; Chengdu University of... and other collaboratorsUnknownDiabetic Peripheral Neuropathy Type 2China
-
Heidelberg Engineering GmbHCompletedNormal Eyes of Subjects Without Diabetes Mellitus | Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN | Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN
-
Aalborg University HospitalRecruitingType 2 Diabetes | Osteoporosis | Diabetic Neuropathy Peripheral | Bone Disease | Autonomic Neuropathy, DiabeticDenmark
Clinical Trials on Metanx (a medical food)
-
Pamlab, L.L.C.InfoMedics, Inc.UnknownDiabetic Peripheral NeuropathyUnited States
-
Pamlab, L.L.C.HealthCore, Inc.CompletedDiabetic Peripheral Neuropathy (DPN)United States
-
Rush University Medical CenterPamlab, Inc.CompletedSubjective Memory Loss in Older PersonsUnited States
-
Massachusetts General HospitalPamlab, L.L.C.CompletedMajor Depressive DisorderUnited States
-
Abbott NutritionCompleted
-
Abbott NutritionCompletedHip FractureRussian Federation
-
Romanian Society for Enteral and Parenteral NutritionNot yet recruitingTrauma | Gastroparesis | Muscle Loss | Metabolism | Nutritional Deficiency | Protein Malnutrition | Calorie Malnutrition ProteinRomania
-
Terra Biological LLCBateman Horne CenterRecruitingFatigue Syndrome, Chronic | Post-COVID-19 SyndromeUnited States
-
University of South FloridaRecruiting
-
Faeth TherapeuticsRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic AdenocarcinomaUnited States